Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. (Record no. 23897753)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02383 a2200649 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250516215348.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201408s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1474-547X |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1016/S0140-6736(14)60538-9 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Manns, Michael |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20140818 |
245 00 - TITLE STATEMENT | |
Title | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Lancet (London, England) |
Date of publication, distribution, etc. | Aug 2014 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 414-26 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Adolescent |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Adult |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antiviral Agents |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Double-Blind Method |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Administration Schedule |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Therapy, Combination |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Female |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Genotype |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Hepacivirus |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Hepatitis C, Chronic |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Heterocyclic Compounds, 3-Ring |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Interferon alpha-2 |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Interferon-alpha |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Male |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Middle Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Polyethylene Glycols |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Recombinant Proteins |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Ribavirin |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Simeprevir |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Sulfonamides |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Treatment Outcome |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Marcellin, Patrick |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Poordad, Fred |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | de Araujo, Evaldo Stanislau Affonso |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Buti, Maria |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Horsmans, Yves |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Janczewska, Ewa |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Villamil, Federico |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Scott, Jane |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Peeters, Monika |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Lenz, Oliver |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Ouwerkerk-Mahadevan, Sivi |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | De La Rosa, Guy |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Kalmeijer, Ronald |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Sinha, Rekha |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Beumont-Mauviel, Maria |
773 0# - HOST ITEM ENTRY | |
Title | Lancet (London, England) |
Related parts | vol. 384 |
-- | no. 9941 |
-- | p. 414-26 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1016/S0140-6736(14)60538-9">https://doi.org/10.1016/S0140-6736(14)60538-9</a> |
Public note | Available from publisher's website |
No items available.